Table 2.
Comparison of patient characteristics in the letermovir and control groups
| Characteristic | Before matching | After matching | ||||
|---|---|---|---|---|---|---|
| Control (N = 53) | Letermovir (N = 34) | P | Control (N = 21) | Letermovir (N = 21) | P | |
| Gender, n (%) | 1.000 | 1.000 | ||||
| Female | 26 (49.1) | 17 (50.0) | 11 (52.4) | 10 (47.6) | ||
| Male | 27 (50.9) | 17 (50.0) | 10 (47.6) | 11 (52.4) | ||
| Age at HSCT | 0.369 | 0.842 | ||||
| Mean (SD) | 29.3 (12.3) | 26.8 (12.7) | 28.2 (11.8) | 29.0 (14.2) | ||
| Median (Min, Max) | 28.0 (10.0, 60.0) | 26.5 (5.0, 54.0) | 29.0 (11.0, 59.0) | 30.0 (5.00, 54.0) | ||
| AA, n (%) | 0.966 | 0.582 | ||||
| NSAA | 2 (3.8) | 1 (2.9) | 1 (4.8) | 0 (0) | ||
| SAA | 30 (56.6) | 20 (58.8) | 14 (66.7) | 14 (66.7) | ||
| VSAA | 21 (39.6) | 13 (38.2) | 6 (28.6) | 7 (33.3) | ||
| Interval from diagnosis to HSCT, n (%) | 0.954 | 1.000 | ||||
| < 3 month | 25 (47.2) | 15 (44.1) | 7 (33.3) | 7 (33.3) | ||
| ≥ 3 month | 28 (52.8) | 19 (55.9) | 14 (66.7) | 14 (66.7) | ||
| ECOG score pre-HSCT, n (%) | 0.081 | 1.000 | ||||
| 0–1 | 34 (64.2) | 29 (85.3) | 18 (85.7) | 19 (90.5) | ||
| 2 | 17 (32.1) | 5 (14.7) | 3 (14.3) | 2 (2.5) | ||
| 3 | 2 (3.8) | 0 (0) | ||||
| Age of donor | 0.994 | 0.208 | ||||
| Mean (SD) | 32.0 (11.6) | 32.0 (11.9) | 31.1 (8.55) | 35.4 (12.7) | ||
| Median (Min, Max) | 32.0 (9.00, 57.0) | 30.0 (13.0, 60.0) | 32.0 (19.0, 57.0) | 37.0 (13.0, 60.0) | ||
| Donor-recipient sex match, n (%) | 0.998 | 0.805 | ||||
| Female–female | 5 (9.4) | 3 (8.8) | 1 (4.8) | 2 (9.5) | ||
| Female–male | 21 (39.6) | 13 (38.2) | 10 (47.6) | 8 (38.1) | ||
| Male–female | 9 (17.0) | 6 (17.6) | 4 (19.0) | 3 (14.3) | ||
| Male–male | 18 (34.0) | 12 (35.3) | 6 (28.6) | 8 (38.1) | ||
| Condition regimen, n (%) | 0.323 | 0.635 | ||||
| BuCy | 8 (15.1) | 3 (8.8) | 5 (23.8) | 6 (28.6) | ||
| FCA | 5 (9.4) | 5 (14.7) | 3 (14.3) | 2 (9.5) | ||
| PTCy | 17 (32.1) | 11 (32.4) | 4 (19.0) | 7 (33.3) | ||
| PTCy-Bu | 23 (43.4) | 9 (26.5) | 9 (42.9) | 6 (28.6) | ||
| Donor type, n (%) | 0.140 | 0.572 | ||||
| MSD | 16 (30.2) | 15 (44.1) | 10 (47.6) | 8 (38.1) | ||
| MUD | 10 (18.9) | 9 (26.5) | 7 (33.3) | 6 (28.6) | ||
| HID | 27 (50.9) | 10 (29.4) | 4 (19.0) | 7 (33.3) | ||
| ABO match, n (%) | 0.226 | 1.000 | ||||
| Matched | 27 (50.9) | 12 (35.3) | 8 (38.1) | 8 (38.1) | ||
| Mismatched | 26 (49.1) | 22 (64.7) | 13 (61.9) | 13 (61.9) | ||
SD standard deviation, NSAA non-severe aplastic anemia, SAA severe aplastic anemia, VSAA very severe aplastic anemia, ATG anti-thymocytes globulin, BuCy busulfan + cyclophosphamide + anti-human thymocyte immunoglobulin,
FCA fludarabine + cyclophosphamide + anti-thymocyte globulin, Bu busulfan, PTCy fludarabine + cyclophosphamide + anti-thymocyte globulin + posttransplant cyclophosphamide ± TBI, PTCy-Bu fludarabine + cyclophosphamide + anti-thymocyte globulin + posttransplant cyclophosphamide + busulfan, MSD matched sibling donor, MUD matched unrelated donor, HID haploidentical